(Q37362652)

19 August 2017

1 reference

title

Novel targets in the management of pneumonia (English)

1 reference

19 August 2017

0 references

3

Antonio Anzueto

1 reference

19 August 2017

Luis A Díaz

1

1 reference

19 August 2017

Eric M Mortensen

series ordinal

2

1 reference

19 August 2017

Marcos I Restrepo

series ordinal

4

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Therapeutic advances in respiratory disease

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

387-400

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Validation of a predictive rule for the management of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Novel approaches to the treatment of bacterial lower respiratory tract infections: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Review: granulocyte colony-stimulating factor--role and relationships in infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Validation of predictive rules and indices of severity for community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Severe community-acquired pneumonia. Assessment of severity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Effects of systemic steroids in patients with severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Overview of nosocomial infections caused by gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Circulating interleukin 6 and interleukin 10 in community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Antimicrobial treatment of lower respiratory tract infections in the hospital setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Quality of care, process, and outcomes in elderly patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Community acquired pneumonia: aetiology and usefulness of severity criteria on admission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

The cost of treating community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

How can clinicians measure safety and quality in acute care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Patterns of cytokine expression in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Optimizing therapy for MRSA pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Filgrastim in patients with pneumonia and severe sepsis or septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

Severe Community-Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808098694

21 January 2018

Identifiers

DOI

10.1177/1753465808098694

1 reference

19 August 2017

1 reference